The financing round was backed by Maven Capital Partners, YFM Equity Partners, Triple Point Ventures, and regional funds to support US growth.
"Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process."
NPIF - Maven Equity Finance led the funding round, with additional backing from the Future Fund, to support the company as it expands its customer reach.
"At the heart of the eviid platform sits our unique patented evidential technology as well as a robust system for handling video in enterprise contexts. It’s incredibly scalable, with applications in numerous sectors beyond the ones we are serving today. The pandemic has really put video on the map and businesses around the world have realised how much can be done remotely. We have a long-term solution for this – a secure and proven system for integrating video and images into business workflows."
